Form 4: Caris Life Sciences Director Reports Significant Stock Holdings Post-Reverse Split and IPO Conversion

A recent SEC Form 4 filing reveals Caris Life Sciences Director Jon Halbert's acquisition of restricted stock units and the conversion of preferred stock into common shares following the company's initial public offering and a one-for-four reverse stock split.

Summary

• Jon Halbert, a Director of Caris Life Sciences, Inc., reported changes in his beneficial ownership of company securities.
• On February 27, 2025, Halbert acquired 16,129 shares of Common Stock, representing an award of restricted stock units (RSUs) that vest in accordance with a grant agreement.
• On June 20, 2025, 5,000,000 shares of Series A Preferred Stock held indirectly by Ke'Ohana Ventures, LLC were automatically converted into 1,250,000 shares of Common Stock.
• This conversion occurred upon the closing of Caris Life Sciences' initial public offering (IPO), with each preferred share converting into 0.25 shares of Common Stock.
• All securities reported in this Form 4 reflect a one-for-four reverse stock split that was effected as of June 1, 2025.
• Following these transactions, Halbert beneficially owns 116,129 shares of Common Stock directly and 1,250,000 shares of Common Stock indirectly through Ke'Ohana Ventures, LLC.

Sentiment

Score: 6

Explanation: The document reports standard insider transactions related to an IPO and RSU awards, which are generally neutral to slightly positive as they align insider interests with the company's performance. No negative financial or operational news is present.

Positives

• The acquisition of 16,129 restricted stock units by a director can signal alignment of management interests with shareholder value.
• The conversion of preferred stock into common stock is a standard event associated with an IPO, simplifying the capital structure.

Future Outlook

The document indicates the closing of the Issuer's initial public offering (IPO), which is a past event, but does not provide specific forward-looking statements or guidance regarding future company performance or strategy.

Management Comments

• The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein regarding shares held by Ke'Ohana Ventures, LLC.

Industry Context

This Form 4 filing is specific to insider trading disclosures and does not provide broader industry context or trends. It reflects a standard reporting requirement for directors' and officers' transactions in their company's securities, particularly following significant corporate events like an IPO and stock split.

Related Party Transactions

• Jon Halbert's indirect beneficial ownership of 1,250,000 Common Stock shares through Ke'Ohana Ventures, LLC, with a disclaimer of beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders are impacted by the one-for-four reverse stock split, which reduces the number of outstanding shares and proportionally increases the share price.
• Shareholders are also impacted by the conversion of preferred stock to common stock, which simplifies the capital structure and increases the common share float.
• The reporting of director stock holdings provides transparency to investors regarding insider ownership.

Key Dates

Keywords

Caris Life Sciences, Form 4, Insider Transaction, Restricted Stock Units, Preferred Stock Conversion, Reverse Stock Split, IPO, Beneficial Ownership, Director Holdings